TrialNeurology(R) neuroimmunology & neuroinflammation2022

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

Patrick Vermersch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.